The 7 stocks in munKNEE’s American Cannabis MSOs Index are experiencing a welcome rebound, up 10.8% the week ending November 11th on top of a 14.1% surge the previous week following declines of 21.4% and 15.0% in the 2 weeks before that.Below are the performances of the 7 constituents in descending order based on their sum total valuation metrics (price-to-earnings (P/E) ratio, forward-price-to-sales ratio (PSR), and enterprise value-to-earnings before interest, taxes, depreciation and amortization (EV/EBITDA) ratio) along with their individual valuation metrics to provide a comparative valuation of each, their performances YTD and any recent news about them. A definition of each ratio is at the end of the article. American Cannabis MSOs Index
- has a forward Price Earnings (P/E) ratio of (No earnings)
- has a forward Price-to-Sales Ratio (PSR) of 0.9
- has an EV/EBITDA ratio of 5.5
- is down 25.8% YTD
- Read: Trulieve Cannabis Q3 Financials Show Major Improvement In Net Loss
- has a forward Price Earnings (P/E) ratio of (No earnings)
- has a forward Price-to-Sales Ratio (PSR) of 0.7
- has an EV/EBITDA ratio of 6.8
- is down 21.1% YTD
- Read: Cresco Labs to Report Third Quarter 2023 Financial Results on November 15, 2023
- has a forward Price Earnings (P/E) ratio of (No earnings)
- has a forward Price-to-Sales Ratio (PSR) of 1.6
- has an EV/EBITDA ratio of 6.2
- is up 46.1% YTD
- Read: Verano Holdings’ Q3 Financials
- has a forward Price Earnings (P/E) ratio of (No earnings)
- has a forward Price-to-Sales Ratio (PSR) of 0.3
- has an EV/EBITDA ratio of 8.4
- is down 42.0% YTD
- Read: The Cannabist Company to Report Third Quarter 2023 Results on November 14, 2023
- has a forward Price Earnings (P/E) ratio of 55.4 (High – sector median of 18.4)
- has a forward Price-to-Sales Ratio (PSR) of 2.2
- has an EV/EBITDA ratio of 10.8
- is up 17.0% YTD
- Read: Green Thumb Q3 Financial Metrics Are All Up
- has a forward Price Earnings (P/E) ratio of (No earnings)
- has a forward Price-to-Sales Ratio (PSR) of 1.5
- has an EV/EBITDA ratio of 10.3
- is up 54.8% YTD
- Read: TerrAscend’s Q3 Net Revenue And Adj. EBITDA Increased 24% And 89%, Respectively
- has a forward Price Earnings (P/E) ratio of 131.2 (High – sector median of 18.4)
- has a forward Price-to-Sales Ratio (PSR) of 1.8
- has an EV/EBITDA ratio of 11.0
- is down 17.4% YTD
- Read: Curaleaf Q3 Financials Report 24% Increase In Net Loss
MSO Stock Performance SummaryIndex Average: up 10.8% last week and up 14.1% the previous week but still down 0.1% YTD.If you are interested in the cannabis category, consider:
Understanding Valuation Metrics To evaluate these companies, investors often look at several key ratios:
These metrics are essential for investors to understand the financial health and potential of companies within the Health Care/Pharmaceuticals sector.More By This Author:Conservative “Cannabis” Stocks Index Reduced To 5 Constituents
Psychedelic Compound-Based R&D Stocks Not For The Faint Of Heart
If EDA Software Is The Next Big Thing, Who Is Best Positioned To Capitalize?
